CSF1 and prostate carcinoma: The anti-CSF-1 antibody LY302285 (IMC-CS4) also resulted in liver enzyme elevations and minimal efficacy in a phase I dose-escalation trial in solid tumors [18], and minimal toxicity in a second study in patients with refractory breast and prostate cancer, with a best response of stable disease [16].